Antineoplaston As2-1/Antineoplaston A10

N/A

Report date: 2024/07/30 17:49:27

Base Information

Drug NameAntineoplaston As2-1/Antineoplaston A10
Drug Alias NameAtengenal / AstugenalAntineoplaston A10/antineoplaston As2-1Antineoplastons A10/AS2-1Antineoplastons therapyAstugenal (AS2-1) +[13] 
ClassificationSmall molecules
Mechanisms of ActionApoptosis inducersCell cycle inhibitorsApoptosis stimulants
TargetsNot applicable
Therapy Area/IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsVulvar Neoplasms +[35] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Antineoplaston A10NSC-620621
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBurzynski Research Institute (Bri)
China Registration ClassN/A

Develop Information

Active CompaniesBurzynski Research Institute Inc
Inactive CompaniesBurzynski Research Institute (Bri)
Active IndicationsGlioma
Inactive IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsVulvar Neoplasms +[34] 

Other Information

ATC CodeN/A
Related LinksN/A